Cargando…
Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases
The treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation is difficult due to the lack of effective treatment options. The available evidence on the emerging immunotherapy in liver transplantation is based on anecdotal experiences and requires additional investigations. T...
Autores principales: | Al Jarroudi, Ouissam, Ulusakarya, Ayhan, Almohamad, Wathek, Afqir, Said, Morere, Jean-Francois |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586420/ https://www.ncbi.nlm.nih.gov/pubmed/33133796 http://dx.doi.org/10.7759/cureus.11150 |
Ejemplares similares
-
Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience
por: Al jarroudi, Ouissam, et al.
Publicado: (2021) -
Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma
por: Ulusakarya, Ayhan, et al.
Publicado: (2019) -
Bevacizumab in metastatic colorectal cancer in a real-life setting – toxicity profile, survival outcomes, and impact of tumor sidedness
por: Chibani, Hind, et al.
Publicado: (2022) -
Ovarian cancer in Morocco: Time to act is now
por: El Bairi, Khalid, et al.
Publicado: (2021) -
Tracing ovarian cancer research in Morocco: A bibliometric analysis
por: El Bairi, Khalid, et al.
Publicado: (2021)